1. Home
  2. NBY vs CTNM Comparison

NBY vs CTNM Comparison

Compare NBY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

N/A

Current Price

$4.67

Market Cap

398.2M

Sector

N/A

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$12.64

Market Cap

416.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NBY
CTNM
Founded
2000
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
398.2M
416.1M
IPO Year
2007
2024

Fundamental Metrics

Financial Performance
Metric
NBY
CTNM
Price
$4.67
$12.64
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.00
AVG Volume (30 Days)
2.3M
251.3K
Earning Date
11-07-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$10,302,000.00
N/A
Revenue This Year
$23.91
N/A
Revenue Next Year
$32.05
N/A
P/E Ratio
$177.57
N/A
Revenue Growth
390.34
N/A
52 Week Low
$0.46
$3.35
52 Week High
$6.47
$15.25

Technical Indicators

Market Signals
Indicator
NBY
CTNM
Relative Strength Index (RSI) 71.81 61.13
Support Level $4.37 $11.27
Resistance Level $6.47 $12.00
Average True Range (ATR) 0.89 0.70
MACD 0.28 0.07
Stochastic Oscillator 67.28 69.75

Price Performance

Historical Comparison
NBY
CTNM

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: